| [1] |
Connor AA, Gallinger S. Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data[J]. Nat Rev Cancer, 2022, 22(3): 131-142.
|
| [2] |
Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities[J]. Nat Rev Clin Oncol, 2020, 17(9): 527-540.
|
| [3] |
Pang T, Wilson JS, Apte MV. Pancreatic stellate cells: what’s new?[J]. Curr Opin Gastroenterol, 2017, 33(5): 366-373.
|
| [4] |
Olivares O, Mayers JR, Gouirand V, et al. Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions[J]. Nat Commun, 2017, 8: 16031.
|
| [5] |
Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts[J]. Nat Rev Drug Discov, 2019, 18(2): 99-115.
|
| [6] |
Biffi G, Oni TE, Spielman B, et al. IL1-induced JAK/STAT signaling is antagonized by TGF-β to shape CAF heterogeneity in pancreatic ductal adenocarcinoma[J]. Cancer Discov, 2019, 9(2): 282-301.
|
| [7] |
Elyada E, Bolisetty M, Laise P, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts[J]. Cancer Discov, 2019, 9(8): 1102-1123.
|
| [8] |
Moore MJ, Hamm J, Dancey J, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 2003, 21(17): 3296-3302.
|
| [9] |
Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer[J]. Brit J Cancer, 2002, 87(2): 161-167.
|
| [10] |
Whatcott CJ, Diep CH, Jiang P, et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer[J]. Clin Cancer Res, 2015, 21(15): 3561-3568.
|
| [11] |
Hingorani SR, Zheng L, Bullock AJ, et al. HALO 202: randomized phase Ⅱstudy of PEGPH20 plus Nab-paclitaxel/gemcitabine versus Nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma[J]. J Clin Oncol, 2018, 36(4): 359-366.
|
| [12] |
Ramanathan RK, McDonough SL, Philip PA, et al. Phase ⅠB/Ⅱ randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus folfirinox alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313[J]. J Clin Oncol, 2019, 37(13): 1062-1069.
|
| [13] |
Van Cutsem E, Tempero MA, Sigal D, et al. Randomized phase Ⅲ trial of pegvorhyaluronidase Alfa with Nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma[J]. J Clin Oncol, 2020, 38(27): 3185-3194.
|
| [14] |
Bailey JM, Swanson BJ, Hamada T, et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer[J]. Clin Cancer Res, 2008, 14(19): 5995-6004.
|
| [15] |
Catenacci DV, Junttila MR, Karrison T, et al. Randomized phase Ⅰb/Ⅱ study of gemcitabine plus placebo or Vismodegib, a Hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer[J]. J Clin Oncol, 2015, 33(36): 4284-4292.
|
| [16] |
De Jesus-Acosta A, Sugar EA, O’Dwyer PJ, et al. Phase 2 study of Vismodegib, a hedgehog inhibitor, combined with gemcitabine and Nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma[J]. Br J Cancer, 2020, 122(4): 498-505.
|
| [17] |
Principe DR, Doll JA, Bauer J, et al. TGFβ: duality of function between tumor prevention and carcinogenesis[J]. J Natl Cancer Inst, 2014, 106(2): djt369.
|
| [18] |
Melisi D, Garcia-Carbonero R, Macarulla T, et al. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer[J]. Br J Cancer, 2018, 119(10): 1208-1214.
|
| [19] |
Diop-Frimpong B, Chauhan VP, Krane S, et al. Losartan inhibits collagenⅠsynthesis and improves the distribution and efficacy of nanotherapeutics in tumors[J]. Proc Natl Acad Sci U S A, 2011, 108(7): 2909-2914.
|
| [20] |
Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase 2 clinical trial[J]. JAMA Oncol, 2019, 5(7): 1020-1027.
|
| [21] |
Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma[J]. Nat Genet, 2015, 47(10): 1168-1178.
|
| [22] |
Shi S, Liang C, Xu J, et al. The strain ratio as obtained by endoscopic ultrasonography elastography correlates with the stroma proportion and the prognosis of local pancreatic cancer[J]. Ann Surg, 2020, 271(3): 559-565.
|
| [23] |
Attiyeh MA, Chakraborty J, McIntyre CA, et al. CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma[J]. Abdom Radiol (NY), 2019, 44(9): 3148-3157.
|
| [24] |
Torphy RJ, Wang Z, True-Yasaki A, et al. Stromal content is correlated with tissue site, contrast retention, and survival in pancreatic adenocarcinoma[J]. JCO Precis Oncol, 2018, 2018.
|
| [25] |
Erstad DJ, Sojoodi M, Taylor MS, et al. Fibrotic response to neoadjuvant therapy predicts survival in pancreatic cancer and is measurable with collagen-targeted molecular MRI[J]. Clin Cancer Res, 2020, 26(18): 5007-5018.
|
| [26] |
Hattori Y, Gabata T, Matsui O, et al. Enhancement patterns of pancreatic adenocarcinoma on conventional dynamic multi-detector row CT: correlation with angiogenesis and fibrosis[J]. World J Gastroenterol, 2009, 15(25): 3114-3121.
|
| [27] |
Hashimoto Y, Sclabas GM, Takahashi N, et al. Dual-phase computed tomography for assessment of pancreatic fibrosis and anastomotic failure risk following pancreatoduodenectomy[J]. J Gastrointest Surg, 2011, 15(12): 2193-2204.
|
| [28] |
Sofue K, Ueshima E, Masuda A, et al. Estimation of pancreatic fibrosis and prediction of postoperative pancreatic fistula using extracellular volume fraction in multiphasic contrast-enhanced CT[J]. Eur Radiol, 2022, 32(3): 1770-1780.
|
| [29] |
Wang Y, Chen ZE, Nikolaidis P, et al. Diffusion-weighted magnetic resonance imaging of pancreatic adenocarcinomas: association with histopathology and tumor grade[J]. J Magn Reson Imaging, 2011, 33(1): 136-142.
|
| [30] |
Noda Y, Goshima S, Tanaka K, et al. Findings in pancreatic MRI associated with pancreatic fibrosis and HbA1c values[J]. J Magn Reson Imaging, 2016, 43(3): 680-687.
|
| [31] |
Schawkat K, Eshmuminov D, Lenggenhager D, et al. Preoperative evaluation of pancreatic fibrosis and lipomatosis: correlation of magnetic resonance findings with histology using magnetization transfer imaging and multigradient echo magnetic resonance imaging[J]. Invest Radiol, 2018, 53(12): 720-727.
|
| [32] |
Yoon JH, Lee JM, Lee KB, et al. Pancreatic steatosis and fibrosis: quantitative assessment with preoperative multiparametric MR imaging[J]. Radiology, 2016, 279(1): 140-150.
|
| [33] |
Liu C, Shi Y, Lan G, et al. Evaluation of pancreatic fibrosis grading by multiparametric quantitative magnetic resonance imaging[J]. J Magn Reson Imaging, 2021, 54(5): 1417-1429.
|
| [34] |
Shi Y, Liu Y, Gao F, et al. Pancreatic stiffness quantified with MR elastography: relationship to postoperative pancreatic fistula after pancreaticoenteric anastomosis[J]. Radiology, 2018, 288(2): 476-484.
|
| [35] |
Itoh Y, Itoh A, Kawashima H, et al. Quantitative analysis of diagnosing pancreatic fibrosis using EUS-elastography (comparison with surgical specimens)[J]. J Gastroenterol, 2014, 49(7): 1183-1192.
|